Vnitr Lek 2018, 64(12):1124-1128

A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis

Vladimír Soška1,2,*, David Karásek3, Vladimír Blaha4, Renata Cífková5, Tomáš Freiberger6, Pavel Kraml7, Jan Piťha8,9, Hana Rosolová10, Tomáš Štulc11, Zuzana Urbanová12, Michal Vrablík11
1 Oddělení klinické biochemie FN u sv. Anny v Brně
2 II. interní klinika LF MU a FN u sv. Anny v Brně
3 III. interní klinika - nefrologická, revmatologická a endokrinologická LF UP a FN Olomouc
4 III. interní gerontometabolická klinika LF UK a FN Hradec Králové
5 Centrum kardiovaskulární prevence 1. LF UK a Thomayerovy nemocnice, Praha
6 Centrum kardiovaskulární a transplantační chirurgie, Brno
7 II. interní klinika 3. LF a FN Královské Vinohrady, Praha
8 Interní klinika 2. LF UK a FN Motol, Praha
9 Laboratoř pro výzkum aterosklerózy IKEM, Praha
10 II. interní klinika LF UK a FN Plzeň
11 III. interní klinika 1. LF UK a VFN v Praze
12 Klinika dětského a dorostového lékařství 1. LF UK a VFN v Praze

This article summarised opinion of the European Society for Atherosclerosis on the causal relationship between low density lipoprotein (LDL) and the development of atherosclerosis. The fact that there is a clear causal relationship between the LDL concentration and the development of atherosclerotic cardiovascular disease (ASKVO) is evidenced by congenital lipid metabolism disorders and results of prospective epidemiological studies, Mendelian randomized trials, and randomized controlled trials. It is documented that the effect of LDL exposure on ASKVO development is cumulative; the additive effect of other risk factors is also discussed. In conclusion the facts, underlying the rational approach to the therapy of patients with dyslipidemia, are summarized.

Keywords: atherosclerotic cardiovascular disease; LDL; low density lipoprotein; EAS

Received: June 16, 2018; Published: December 1, 2018  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Soška V, Karásek D, Blaha V, Cífková R, Freiberger T, Kraml P, et al.. A summary of the EAS consensus concerning the causal relationship between low-density lipoproteins and atherosclerotic cardiovascular diseases, prepared by the Board of the Czech Society for Atherosclerosis. Vnitr Lek. 2018;64(12):1124-1128.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J 2017; 38(32): 2459-2472. Dostupné z DOI: <http://dx.doi.org/10.1093/eurheartj/ehx144>. Go to original source... Go to PubMed...
    2. Di Angelantonio E, Sarwar N et al. [Emerging Risk Factors Collaboration]. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009; 302(18): 1993-2000. Dostupné z DOI: <http://dx.doi.org/10.1001/jama.2009.1619>. Go to original source... Go to PubMed...
    3. Lewington S, Whitlock G, Clarke R et al. [Prospective Studies Collaboration]. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 2007; 370(9602): 1829-1839. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(07)61778-4>. Erratum in Lancet 2008; 372(9635): 292. Go to original source... Go to PubMed...
    4. Ference BA, Yoo W, Alesh I et al. Effect of Long-Term Exposure to Lower Low-Density Lipoprotein Cholesterol Beginning Early in Life on the Risk of Coronary Heart Disease A Mendelian Randomization Analysis. J Am Coll Cardiol 2012; 60(25): 2631-2639. Dostupné z DOI: <http://dx.doi.org/10.1016/j.jacc.2012.09.017>. Go to original source... Go to PubMed...
    5. Baigent C, Blackwell L, Emberson J et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376(9753): 1670-1681. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(10)61350-5>. Go to original source... Go to PubMed...
    6. Piepoli MF, Hoes AW, Agewall S et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016; 252: 207-274. Dostupné z DOI: <http://dx.doi.org/10.1016/j.atherosclerosis.2016.05.037>. Go to original source... Go to PubMed...
    7. Mega JL, Stitziel NO, Smith JG et al. Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials. Lancet 2015; 385(9984): 2264-2271. Dostupné z DOI: <http://dx.doi.org/10.1016/S0140-6736(14)61730-X>. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.